Biosimilars and Biologic Distribution: How a $72B Market Is Rewriting the Supply Chain Playbook
The U.S. spent roughly $400 billion on specialty drugs in 2022. A record $9.4 billion of that was clawed back […]
The U.S. spent roughly $400 billion on specialty drugs in 2022. A record $9.4 billion of that was clawed back […]
The Unified Patent Court went live on June 1, 2023. Pharma IP teams and biotech portfolio managers who treated that
The Economics Behind Low-Competition Generic Markets Why Price Decay Makes Niche Sourcing Mandatory Generic drug markets operate on a compression
1. Who This Guide Is For This guide is written for IP counsel, portfolio managers, R&D leads, and institutional investors
AI Drug Patents: The Complete IP Strategy Guide for Pharma and Biotech Read Post »
Executive Summary The global biopharmaceutical sector has entered a decisive inflection point in early 2026, characterized by the convergence of
What Patent Timing Actually Decides A pharmaceutical patent filed on Day 1 of discovery and a patent filed after Phase
The Power of Patience: The Pharma Playbook for Extending Market Exclusivity Read Post »
Atorvastatin lost its primary patent on November 30, 2011. What followed was the most studied loss-of-exclusivity response in pharmaceutical history.
1. Why Patent Portfolio Management Determines Market Survival Pharmaceutical patent portfolio management is not a legal overhead function. It is
Drug Patent Portfolio Management: The Definitive Playbook for Pharma IP Teams Read Post »
Why China’s Patent System Demands Your Full Attention Now China filed more than 1.5 million patent applications in 2022, making
Sign in or create a free account to read this DrugPatentWatch article